Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five…
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel,…
University of Phoenix College of Doctoral Studies Releases White Paper on Workplace Optimism as a Value-added Requirement for Companies
Authors Dr. Julie Overbey and Dr. Pamela Ann Gordon explore value of…
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritisPivotal clinical trial…
HRH The Duke of Edinburgh visits Peterborough boxing charity
Monday 3 March, 2025 HRH The Duke of Edinburgh heard about the…
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part…
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody,…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need…
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the…
